Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent Study finds preliminary signs the therapy might tamp down a class of immune signals linked with chronic conditions

https://www.statnews.com/2025/06/02/kymera-therapy-results-dupixent-rival-sanofi-regeneron/